Microbix Biosystms (MBX) AI Stock Analysis

• Market Cap: C$41.47M
• Dividend Yield: N/A
• Average Volume (3M): 53.37K
• Price to Earnings (P/E): 25.4
• Beta (1Y): -0.28
• Revenue Growth: -4.67%
• EPS Growth: -60.94%
• Country: CA
• Employees: 100
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): 0.00
• Shares Outstanding: 140,561,450
• 10 Day Avg. Volume: 53,497
• 30 Day Avg. Volume: 53,370
• PEG Ratio: -1.39
• Price to Book (P/B): 1.33
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 18.44
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$0.50
• Price Target Upside: 66.67% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 70 Neutral
• Price Target: C$0.50 ▲(66.67%Upside)

Microbix Biosystems is demonstrating strong financial performance and positive strategic developments, particularly in expanding its market presence and product offerings. However, technical indicators show weakness, and there are concerns about sustaining revenue growth and managing investment demands. The stock is fairly valued with a P/E ratio in line with industry averages, but lacks a dividend yield.

Positive Factors

Market Expansion

The increased adoption in emerging markets and expansion into recombinant antigens suggest continued robust growth.

Revenue Growth

Antigen revenues increased 118% year over year to $4.3 million, indicating strong product performance.

Trade Benefits

Microbix products are exempt from tariffs under the USMCA trade agreement, enabling cost-effective sales into the U.S.

Negative Factors

Market Demand

The unusually light burden of respiratory infectious diseases in China has decreased the demand for Microbix's antigen shipments.

Revenue Decline

Total revenues declined 28% year over year, presenting a challenging financial performance.

Sales Impact

Sales of antigens for Chinese customers have abruptly stopped, impacting a significant portion of the company's revenue.

Microbix Biosystms Business Overview & Revenue Model

Company Description

Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots. It sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs through a network of regional distributors. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.

How the Company Makes Money

Microbix Biosystems generates revenue primarily through the sale of its quality assessment products (QAPs), which are used by laboratories to ensure the accuracy and reliability of diagnostic testing. Additionally, the company earns income from the production and sale of viral antigens for use in immunoassays, which are critical for diagnostic and research applications. They also offer viral transport media, which is essential for the safe transport of clinical specimens. Significant partnerships with healthcare and diagnostic companies, as well as global distribution agreements, contribute to the company's earnings by expanding the reach and adoption of its products worldwide.

Microbix Biosystms Financial Statement Overview

Summary

Microbix Biosystems is showing positive financial trends with improved revenue growth and profitability margins. The balance sheet is stable with decreasing debt levels, and cash flows are increasingly positive. However, potential challenges with maintaining revenue growth and managing investment demands remain.

Income Statement

Microbix Biosystems has shown strong revenue growth from 2020 to 2024, with a significant improvement in net profit margins. The company achieved a positive net income in recent years, contrasting with previous losses. Notably, the TTM (Trailing-Twelve-Months) data indicates a gross profit margin of 56.1% and a net profit margin of 8.3%, pointing to improved profitability. However, the recent decline in total revenue from the annual report suggests potential challenges in maintaining revenue momentum.

Balance Sheet

The company's balance sheet reflects a stable equity base, with a notable decrease in debt levels over the years. The debt-to-equity ratio shows a moderate level of leverage, which is manageable. The equity ratio has been improving, indicating a stronger financial position. However, the biotechnology industry is capital intensive, and continuous investment might affect leverage ratios.

Cash Flow

Microbix Biosystems has demonstrated an improvement in operating cash flow, achieving positive free cash flow in the latest periods. The free cash flow to net income ratio suggests healthy cash generation relative to profits. However, past periods of negative free cash flow highlight potential liquidity risks if revenue declines or investment increases unexpectedly.

Breakdown	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	25.39M	16.51M	19.08M	18.59M	10.52M
Gross Profit	15.39M	7.48M	11.12M	11.04M	4.66M
EBITDA	6.21M	1.96M	3.73M	5.66M	-2.91M
Net Income	3.52M	-39.48K	1.79M	1.63M	-6.23M
Balance Sheet
Total Assets	38.10M	35.65M	33.15M	28.83M	15.60M
Cash, Cash Equivalents and Short-Term Investments	12.96M	11.61M	13.49M	9.99M	92.66K
Total Debt	6.40M	6.65M	5.82M	7.74M	6.17M
Total Liabilities	9.80M	11.03M	8.21M	10.27M	8.98M
Stockholders Equity	28.30M	24.62M	24.94M	18.56M	6.62M
Cash Flow
Free Cash Flow	2.44M	-2.11M	1.44M	804.20K	-805.34K
Operating Cash Flow	4.35M	-1.09M	3.47M	2.11M	8.57K
Investing Cash Flow	-1.91M	-1.02M	-2.03M	-622.34K	-813.91K
Financing Cash Flow	-1.08M	229.21K	2.06M	8.41M	802.43K

Microbix Biosystms Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MBX, the sentiment is Neutral. The current price of 0.3 is above the 20-day moving average (MA) of 0.30, below the 50-day MA of 0.31, and below the 200-day MA of 0.37, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.89 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:MBX.

Microbix Biosystms Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COV	79 Outperform	C$71.29M	18.48	14.51%	―	28.97%	―
MBX	70 Neutral	C$41.47M	25.43	5.32%	―	-4.67%	-60.94%
Sector *	60 Neutral	HK$16.84B	5.17	-7.44%	2.89%	11.55%	-28.15%
ONC	43 Neutral	$155.53M	―	-211.24%	―	―	0.10%
MIR	43 Neutral	C$48.84M	―		―	-33.66%	-48.89%
SVA	33 Underperform	C$57.48M	―	248.46%	―	―	32.71%
HBP	33 Underperform	C$77.12M	―	685.26%	―	―	-50.29%

Microbix Biosystms Corporate Events

Microbix Partners with Bulgaria’s NCIPD to Enhance Diagnostic Test Accuracy

Microbix Biosystems Inc. has entered into a multi-year agreement with Bulgaria’s National Center for Infectious and Parasitic Diseases (NCIPD) to develop new quality assessment products (QAPs) using pathogen seedstocks supplied by NCIPD. This collaboration aims to enhance the accuracy of diagnostic tests for infectious diseases, thereby improving global health outcomes. The agreement will allow Microbix to expand its portfolio of QAPs, leveraging NCIPD’s extensive collection of characterized microorganisms. This strategic partnership is expected to strengthen Microbix’s position in the diagnostics industry by increasing its product offerings and supporting the accuracy of emerging tests for bacterial, parasitic, and viral infections.

The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.80 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Microbix Showcases Diagnostic Innovations at Asia Pacific Conference

Microbix Biosystems Inc. announced its participation in the Asia Pacific Conference on Point of Care Testing for Infectious Diseases in Bangkok, where it will present its quality assessment products (QAPs) that support point-of-care testing. The company will showcase its innovations that ensure diagnostic test accuracy, particularly for infectious diseases relevant to the Asia Pacific region. The presentation will highlight the robust performance of Microbix’s QAPs, which have been crucial in supporting SARS-CoV-2 tests and contributed to the company’s selection as a key quality control device partner in the EPICC initiative for HPV elimination. This engagement is expected to enhance Microbix’s role in point-of-care testing programs and expand its collaborations with diagnostics manufacturers.

The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.80 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Microbix Biosystems Reports Q2 Fiscal 2025 Results with Improved Margins and Cautious Outlook

Microbix Biosystems reported its Q2 fiscal 2025 results, showing a revenue of $5.3 million, a slight decrease from the previous year, but with improved gross margins. The company experienced growth in antigen sales, offset by a decline in QAPs due to delays with a major customer. Despite increased operating expenses, Microbix achieved a positive net income and improved financial strength, with strong cash reserves and liquidity. However, the outlook for the second half of fiscal 2025 is cautious due to reduced sales in China, impacting the company’s future growth prospects.

The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.80 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Microbix and Aurevia Launch Pilot EQA Program for Bacterial Vaginosis Diagnosis

Microbix Biosystems Inc., in collaboration with Aurevia Oy, has launched a pilot external quality assessment (EQA) program aimed at enhancing the proficiency of clinical laboratories in diagnosing bacterial vaginosis (BV) using molecular diagnostic methods. This initiative, which involves the use of Microbix’s QAPs to simulate clinical specimens, is expected to improve diagnostic accuracy and treatment planning for BV and other vaginal infections. The program’s success could lead to its inclusion in Aurevia’s Labquality EQAS portfolio, thereby strengthening Microbix’s position as a key partner in the diagnostics industry.

The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.80 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Microbix Biosystems to Release Q2 Fiscal 2025 Results

Microbix Biosystems Inc. has announced the release of its second quarter fiscal 2025 financial results, scheduled for May 15, 2025. The company will host a webinar to discuss these results, featuring its CEO, CFO, and COO. This event reflects Microbix’s ongoing commitment to transparency and engagement with investors and stakeholders, potentially impacting its market positioning and investor relations.

Microbix Advances Kinlytic Urokinase Production with New CDMO Agreement

Microbix Biosystems Inc. announced that its partner, Sequel Pharma, has signed an agreement with a contract development and manufacturing organization (CDMO) to produce Kinlytic® urokinase, a drug for dissolving blood clots. This agreement aims to resume production for the U.S. market, initially targeting the catheter clearance segment valued at $400 million. The collaboration is expected to enhance Microbix’s market presence and operational capabilities, with future updates anticipated as the project progresses.

Microbix to Present at 2025 Bloom Burton Healthcare Investor Conference

Microbix Biosystems Inc. announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference, which will be held at the Metro Toronto Convention Centre. This event provides Microbix with a platform to connect with Canadian, U.S., and international investors, potentially enhancing its market presence and stakeholder engagement in the healthcare and life sciences sector.